FluoGuide provides update on 2026 outlook and progress
The company reports positive results on milestones with minor timing adjustments, outlining progress in brain and head and neck cancer trials.
See the latest news and media coverage for FluoGuide. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing fluorescent cancer surgery drugs
fluoguide.comLast updated
In short: FluoGuide advanced its lead candidate FG001, securing FDA Fast Track Designation and reporting positive Phase 2 results for oral cancer.
The company reports positive results on milestones with minor timing adjustments, outlining progress in brain and head and neck cancer trials.
Optimal dose 0.30 mg/kg identified in 15 patients; FG001 well tolerated and detected by all near-infrared imaging systems.
The report details FDA IND authorization and Fast Track Designation for FG001, and progress in head and neck cancer program.
Dr. Jane Skjøth-Rasmussen shared data at Brain Tumor Symposium 2026 in Copenhagen, highlighting FG001's potential to improve tumor delineation in meningioma and low-grade glioma surgery.
COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) , a clinical-stage biotech company focused on precision cancer...
COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology...
Visit a quote page and your recently viewed tickers will be displayed here.
Review the current valuation for FluoGuide AS Ordinary Shares (FLUO:XSTO) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company...
Track FluoGuide and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.